Metabolic studies with probucol in hypercholesterolaemia.
Probucol (1 g/day) was administered for 6 months to 16 hypercholesterolaemic patients previously stabilized on diet alone. Total plasma cholesterol fell by 16%, LDL cholesterol by 14% and HDL cholesterol by 41%. The ratio of total cholesterol to HDL cholesterol increased by 40%. Total plasma triglycerides showed a slight upward trend. The extent of the fall in HDL cholesterol was directly proportional to the pre-treatment HDL cholesterol concentration. In 2 patients studied, treatment with Probucol produced a sustained increase in the excretion of endogenous faecal steroids, due to increased faecal bile acids. In 3 patients studied, Probucol increased the degree of cholesterol saturation in gall bladder bile. The Lithogenic Index approximated to pathological levels in 1 patient whose bile was previously relatively saturated with cholesterol. Probucol also appeared to cause a modest reduction in the degree of platelet activation in vivo, with reduced platelet prostaglandin synthesis and reduced release of platelet peptides.
D000328:Adult; D000368:Aged; D001646:Bile / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002784:Cholesterol / Q000378:metabolism; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000378:metabolism*; D008055:Lipids / Q000032:analysis / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology*; D011341:Probucol / Q000494:pharmacology*; D013256:Steroids / Q000378:metabolism
D008055:Lipids; D008074:Lipoproteins; D010636:Phenols; D013256:Steroids; D002784:Cholesterol; D011341:Probucol